TY  - JOUR
T1  - The Clinical and Biological Role of FBLN5 in Gastric Cancer
A1  - Yifan Zhao
A1  - Liang Chen
A1  - Ahmad Fauzi
A1  - Nor Hayati
JF  - Archive of International Journal of Cancer and Allied Science
JO  - Arch Int J Cancer Allied Sci
SN  - 3108-4834
Y1  - 2026
VL  - 6
IS  - 1
DO  - 10.51847/VUGAWqjfk3
SP  - 188
EP  - 206
N2  - Irregular expression of FBLN5 has been linked to different forms of cancer. The present study represents the initial investigation into its clinical and functional importance in gastric cancer (GC). Using data from The Cancer Genome Atlas-GC (TCGA-GC) and Gene Expression Omnibus (GEO) databases, we identified differences in FBLN5 expression and examined its association with clinicopathological features. Survival analysis via a Kaplan–Meier plotter evaluated FBLN5’s influence on patient prognosis, while its biological roles were also explored. Furthermore, we developed a GC tissue microarray and conducted immunohistochemical staining for FBLN5 to validate the results. Western blotting was performed in parallel to establish FBLN5 overexpression in GC. We observed that elevated FBLN5 mRNA levels in GC were associated with an unfavorable prognosis. Increased FBLN5 expression showed notable associations with INFc and N3 lymph node metastasis. Both univariate and multivariate analyses identified FBLN5 expression and lymph node metastasis rate as independent prognostic risk factors for GC patients. These factors can be integrated to generate a nomogram for clinical use. Overall, FBLN5 shows a strong association with poorer outcomes in GC patients and serves as a useful prognostic marker.
UR  - https://smerpub.com/article/the-clinical-and-biological-role-of-fbln5-in-gastric-cancer-qqp6oug28kga1sc
ER  -